This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albert, J Articles by Uhlén, M Search for Related Content PubMed PubMed Citation Articles by Albert, J Articles by Uhlén, M

 Previous Article  |  Next Article 

J Virol. 1992 September; 66(9): 5627-5630

Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.

Department of Virology, National Bacteriological Laboratory, Stockholm, Sweden.

ABSTRACT

The rate of reversion from azidothymidine (zidovudine; AZT) resistance was studied by direct sequencing of human immunodeficiency virus type 1 (HIV-1) virion RNA in sera from four patients who discontinued long-term treatment. Before cessation of treatment, all four patients harbored HIV-1 with multiple mutations reported to confer AZT resistance. In three patients, slow reversions of these mutations starting after 9, 9, and 18 months were detected. The slow reversions indicate that AZT-resistant HIV-1 variants are likely to have an unaltered replicative capacity and pathogenic potential. Furthermore, there were discrepancies between the in vivo RNA sequences and the sequences of virus isolates, indicating that the isolation procedure may select for nonrepresentative virus variants.

This article has been cited by other articles:

• Collins, J. A., Thompson, M. G., Paintsil, E., Ricketts, M., Gedzior, J., Alexander, L. (2004). Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 Mutants. J. Virol. 78: 603-611 [Abstract] [Full Text]  
• de Ronde, A., van Dooren, M., van der Hoek, L., Bouwhuis, D., de Rooij, E., van Gemen, B., de Boer, R., Goudsmit, J. (2001). Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant Virus. J. Virol. 75: 595-602 [Abstract] [Full Text]  
• Imamichi, T., Berg, S. C., Imamichi, H., Lopez, J. C., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thrright-arrowGly) at Codon 69. J. Virol. 74: 10958-10964 [Abstract] [Full Text]  
• Sato, H., Tomita, Y., Shibamura, K., Shiino, T., Miyakuni, T., Takebe, Y. (2000). Convergent Evolution of Reverse Transcriptase (RT) Genes of Human Immunodeficiency Virus Type 1 Subtypes E and B following Nucleoside Analogue RT Inhibitor Therapies. J. Virol. 74: 5357-5362 [Abstract] [Full Text]  
• Vener, T., Nygren, M., Andersson, A., Uhlén, M., Albert, J., Lundeberg, J. (1998). Use of Multiple Competitors for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma. J. Clin. Microbiol. 36: 1864-1870 [Abstract] [Full Text]  
• Eastman, P. S., Mittler, J., Kelso, R., Gee, C., Boyer, E., Kolberg, J., Urdea, M., Leonard, J. M., Norbeck, D. W., Mo, H., Markowitz, M. (1998). Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy. J. Virol. 72: 5154-5164 [Abstract] [Full Text]  
• Yerly, S., Rakik, A., Kinloch De Loes, S., Hirschel, B., Descamps, D., Brun-Vezinet, F., Perrin, L. (1998). Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants. J. Virol. 72: 3520-3523 [Abstract] [Full Text]  
• Harrigan, P. R., Bloor, S., Larder, B. A. (1998). Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro. J. Virol. 72: 3773-3778 [Abstract] [Full Text]  
• McDougall, B., King, P. J., Wu, B. W., Hostomsky, Z., Reinecke, M. G., Robinson, W. E. Jr. (1998). Dicaffeoylquinic and Dicaffeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase. Antimicrob. Agents Chemother. 42: 140-146 [Abstract] [Full Text]